T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to T-DM1
Related studies linked through entity extraction aliases.
Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Trastuzumab & Pertuzumab Followed by T-DM1 in MBC
- Status
- COMPLETED
- Phase
- PHASE2
A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.
- Status
- COMPLETED
- Phase
- PHASE2
HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1
- Status
- COMPLETED
- Phase
- PHASE2